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New hepatitis C virus (HCV) treatments spurred the World Health Organization (WHO) in
2016 to adopt a strategy to eliminate HCV as a public health threat by 2030. To achieve this,
key policies must be implemented. In the absence of monitoring mechanisms, this study
aims to assess the extent of policy implementation from the perspective of liver patient
groups.
Methods
Thirty liver patient organisations, each representing a country, were surveyed in October
2018 to assess implementation of HCV policies in practice. Respondents received two sets
of questions based on: 1) WHO recommendations; and 2) validated data sources verifying
an existing policy in their country. Academic experts selected key variables from each set
for inclusion into policy scores. The similarity scores were calculated for each set with a mul-
tiple joint correspondence analysis. Proxy reference countries were included as the baseline
to contextualize results. We extracted scores for each country and standardized them from
0 to 10 (best).
Results
Twenty-five countries responded. For the score based on WHO recommendations, Bulgaria
had the lowest score whereas five countries (Cyprus, Netherlands, Portugal, Slovenia, and
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Sweden) had the highest scores. For the verified policy score, a two-dimensional solution
was identified; first dimension scores pertained to whether verified policies were in place
and second dimension scores pertained to the proportion of verified policies in-place that
were implemented. Spain, UK, and Sweden had high scores for both dimensions.
Conclusions
Patient groups reported that the European region is not on track to meet WHO 2030 HCV
goals. More action should be taken to implement and monitor HCV policies.
Introduction
Viral hepatitis is one of the leading causes of death and disability worldwide and, since 2013,
has surpassed HIV/AIDS and malaria in terms of annual deaths. An estimated 71 million peo-
ple worldwide live with chronic hepatitis C virus (HCV) infection, including 5.6 million people
in the World Health Organization (WHO) European Region [1]. The largest burden of HCV-
related mortality is caused by liver cirrhosis and liver cancer [2]. In Europe, the populations
most impacted are people who are incarcerated, people living with HIV (PLHIV) men who
have sex with men (MSM), and people who inject drugs (PWID) [3]. According to the Euro-
pean Centre for Disease Prevention and Control (ECDC), in the European Union (EU)/ Euro-
pean Economic Area (EEA), 45.5% of new cases of hepatitis C with transmission information
were attributed to injection drug use [4].
In 2016, WHO set the ambitious goal of eliminating hepatitis B and C as a public health
threat by 2030 in its first viral hepatitis global health sector strategy (GHSS) [5]. Elimination of
viral hepatitis is defined as a 65% reduction in mortality and a 90% (80% for HCV) reduction
in the incidence of viral hepatitis [5]. This goal was soon followed by further specified targets
in the WHO European Region’s Action plan for the health sector response to viral hepatitis [6].
Despite these commitments, many countries have been slow to implement policies to achieve
elimination targets.
Prior to the GHSS, two global viral hepatitis policy monitoring studies were conducted and
highlighted the importance of addressing the viral hepatitis epidemic. These studies were
inspired by the absence of a European or global framework to monitor viral hepatitis policy
and the increasing availability of all-oral, highly effective direct acting antivirals (DAAs) [7, 8].
To advance necessary civil society engagement and to fill the knowledge gap surrounding pol-
icy, the European Liver Patients’ Association (ELPA) commissioned the Hep-CORE study in
2015 as a longitudinal project to monitor viral hepatitis policies in countries where they had
member patient organizations. The Hep-CORE study works with patient groups to monitor
policy implementation, traditionally the role of governments and global bodies. A notable
exception to this is the community response to HIV, with civil society organizations, including
patient groups, playing a pivotal role in the Global AIDS Response Progress Reporting. This
has strengthened formal and informal monitoring functions, which has provided an inclusive
perspective to compare data against reports issued by governments to global governance bod-
ies, including WHO and UNAIDS [9]. Notably, civil society, and HIV community activism
and involvement specifically, have improved policy monitoring, highlighted the needs of mar-
ginalized groups, and fostered effective government and civil society collaboration [10].
In its first two years, Hep-CORE focused on patient group reporting on the existence of
viral hepatitis policies in their country. Results at baseline (2016) showed that there were few
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policies supporting viral hepatitis policy recommendations, and, in 2017, only 52% of Euro-
pean countries had a national viral hepatitis plan or strategy in place [11–13]. In 2018, the Lan-
cet Gastroenterology Hepatology Commission called for measuring national responses to viral
hepatitis to ascertain a country’s progress towards its elimination [14]. Inspired by this call,
Hep-CORE 2018 set out to assess whether known national HCV policies in Europe, the United
Kingdom (UK), and the Mediterranean Basin are functioning in practice and to score the
extent of implementation according to patient advocacy groups.
Methods
Data collection
Participants were recruited through a purposive sampling process. We emailed an invitation
to participate in the survey to one liver patient group in each of the countries where ELPA had
members at the time of 2018 study recruitment. In countries with more than one patient
group, we selected the group that was most involved in viral hepatitis advocacy in collabora-
tion with the President of ELPA. A random sample of participants was not possible as the
number of potential participants per country was often one and at most three. We invited the
participants to complete the survey online using a customised survey link auto-generated by
the Research Electronic Data Capture (REDCap) system, hosted online by Rigshospitalet, Uni-
versity of Copenhagen, Denmark, and distributed to each individual via email. Data were col-
lected in September–October 2018. After data collection, we reviewed data and queried study
participants via email about incomplete, inconsistent, or unclear information. Demographics
and specific detail of who responded were collected, but are not disclosed to protect the ano-
nymity of the respondents.
The survey questions were closed-ended and used a 5-point Likert scale [15]. A free-text
box was available for participants to further comment on their responses. Additionally, to assess
the base knowledge of the study participants, a 4-point scale appeared after each question asking
the participant about their level of knowledge pertaining to the question above. We developed
and revised the survey in accordance with multiple rounds of input from the members of the
multidisciplinary study group, which included patient group representation. The study instru-
ment was piloted in September 2018 with four patient groups from Egypt, Finland, Slovenia,
and the UK and revised accordingly. We created and managed the final survey using REDCap.
We surveyed 30 patient groups each representing one country in the EU, Mediterranean
basin, and the UK (in the EU at the time of the study). The study instrument comprised 23
questions derived from previous Hep-CORE surveys, peer-reviewed publications, verified data
sources, expert group consultation, and the Global Health Sector Strategy (GHSS) [5, 16–20].
A full-length copy of the questionnaire is available in appendix 1. One community representa-
tive from each organization was responsible for completing the survey in collaboration with
the organization´s board members.
The survey comprised two sets of questions: those based on WHO recommendations from
the GHSS and those based on verified data sources like the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA). The first set of questions (WHO recommendations)
were provided to all countries and were based off the GHSS to assess implementation of WHO
recommendations. The second set of questions (verified policy) were only sent to countries
that had validated data sources confirm the presence of policies to assess implementation of
these existing policies (Table 1). The data sources for the verified policies were selected as they
either reported novel, raw data that informed the question that it was verifying or because they
were reports from organizations that were responsible for collecting the monitoring data that
underlie specific questions.
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Data analysis
We descriptively and geospatially analysed final data using R 3.6.2 and Microsoft Excel 2017
version 15.31 for storage. Frequencies and count summaries were carried out for every ques-
tion for all of the possible respondents. We further estimated two sets of similarity scores that
we describe below.
Policy similarity score estimation. In addition to descriptive statistics, we used the multi-
ple correspondence analysis (MCA), a dimension reduction method to evaluate the similarity
between patient group responses from different countries [21, 22]. In an MCA, the chi-squared
distance is calculated between the response patterns of all the individuals. The percentage of
the total variation explained is calculated for each of the new dimensions, and the new dimen-
sions are called components [23]. The coordinates of each country (the row profiles) in the
lower dimensional space are extracted and used as a similarity score between country respon-
dents [23]. We used similarity score estimates to construct an HCV policy implementation
score. The similarity score was standardized to be out of 10 points using the standard min-
max normalization method [24].
Table 1. Main HepCORE 2018 survey questions.
Main question (number of sub
questions)
Number of countries where question
is relevant (1–25)
Data source
Elimination efforts HCV (NA) 25 Polaris/GHSS
Policy barriers equity (NA) 25 GHSS
Policy stigma and discrimination (NA) 25 GHSS
Policy HCV strategy/action plan (NA) 23 GHSS/Hep-CORE 2017 [11]
Policy HCV strategy/action plan
comprehensive (6)
11 GHSS
Non-hospital testing (NA) 12 HIV in Europe unpublished data
Non-hospital treatment (NA) 5 Marshall 2018a [18]
Non-specialist treatment (NA) 1 Marshall 2018a [18]
Monitoring implementation (NA) 25 GHSS
Integration of HCV services with
existing care (9)
25 GHSS
Targeting of special populations for
elimination (14)
25 GHSS
Fibrosis HCV treatment restrictions
(NA)
12 Marshall 2018b [17] modified to
add Denmark
Drug and alcohol treatment restriction
(NA)
18 Marshall 2018a [18]
Needle syringe programme general
population (NA)
21 EMCDDA
Opioid substitution therapy general
population (NA)
21 EMCDDA
Needle syringe programme prison
(NA)
3 Bielen et al. 2018 [16]
Opioid substitution therapy prison
(NA)
16 EMCDDA
Testing and screening for HCV in
prisons (NA)
16 Bielen et al. 2018 [16]
HCV treatment in prisons (NA) 16 Bielen et al. 2018 [16]
Questions derived from the GHSS were received by all participants, whereas the other data sources are the verified
policy questions and were received only by selected countries that had the verified policy in place. Questions derived
from EMCDDA data indicate that the information is derived from the country profiles of the European Monitoring
Centre for Drugs and Drug Addiction.
https://doi.org/10.1371/journal.pone.0235715.t001
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We developed two similarity scores: one based on WHO recommendation questions,
received by all respondents, and another based on the verified policy questions, which were
only sent to countries with the relevant policy in place. For the first similarity score for WHO
recommendations, only a subset of the variables were included as we wanted to only incorpo-
rate variables that would be indicative of a country’s commitment to HCV elimination as
determined by multidisciplinary academic experts who were part of the study group. Fifteen
experts were consulted by online questionnaire using SurveyMonkey. The survey used a
5-point Likert scale to evaluate which micro-elimination (targeted elimination that focuses on
specific populations or geographies) and service integration variables the experts considered
most important for inclusion into the score [25]. Questions that received a majority (greater
than 50%) of positive responses were included into the score. The questionnaire is presented
in appendix 2. The selected variables were then coded as 0 or 1 based on patient responses,
with 0 representing a neutral, weak negative, or strong negative response, and 1 representing a
slight positive or a strong positive response. We then applied the MCA to the coded data to
generate the first similarity score.
The second similarity score was based on questions regarding verified policies. We used a
subset of the questions about these policies, excluding questions with low numbers of respon-
dents or low relevance, as determined during the expert consultation. The final verified ques-
tions were coded with three levels to capture the hierarchical nature of the question. The first
level was coded as 0 and represented a country not receiving a question owing to not having
that policy in place. The second level was coded as 1 and was assigned when a country had a
verified policy in place and the patient group for that country responded with a weak negative
or a strong negative response, indicating a lower level of implementation. The final level was
coded as 2, which indicated that a country had a verified policy in place, and the patient
respondent indicated a neutral, weak positive, or strong positive response to the implementa-
tion of said policy. In this analysis, Egypt, Israel, North Macedonia, Switzerland, and Turkey
were excluded due to the lack of verified policies for opioid substitution therapy (OST) and
needle syringe programmes (NSP) in the general population questions because the EMCDDA
did not collect the information for these questions in these countries [20]. For the remaining
countries, we then applied the MCA to the coded data to generate the second similarity score.
Proxy reference countries StagNation (no policies in place) and ElimiNation (all policies in
place and implemented) were included as baseline in the first similarity score. In the second
policy similarity score, ProcrastiNation (all policies, but none implemented) was also included
so that the minimum and maximum of the similarity scores were representative of no imple-
mentation and maximum possible implementation respectively.
Ethics
Since the study was approved and the data were stored in Denmark, we did not need ethics
approval in any other country. According to the regional representative of the Danish data
protection agency and the Barcelona Institute for Global Health (ISGlobal), this study was not
considered human subjects research and therefore did not require ethical review or approval.
We stored all raw data on secure servers in the Capital Region of Denmark and the data were
managed according to Danish regulations. All off the code and data to reproduce this analysis
can be found at https://osf.io/mh79q/.
Results
Participants in 25 of 30 (83.3%) countries responded. Two of the countries that responded
were from the Mediterranean Basin and 23 countries were from the EU/EEA or the UK.
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The results of responses to the questions were considered for the policy similarity scores are
presented in Table 2. Among WHO recommendation variables considered for inclusion, we
limited the expert selection to only the micro-elimination and service integration subsets of
questions (Table 2) as these questions fall along the same underlying concept. Experts indi-
cated that for the micro-elimination variables, responses on migrants, PWID, prisoners, and
sex workers were the most important for inclusion. For the service integration variables, the
experts highlighted the importance of HCV service integration with blood safety, harm reduc-
tion, and migrant health services. We used the binary responses to these seven items to gener-
ate the first similarity score for the countries.
In the MCA for WHO recommendations, the first component accounted for 75.5% of the
total inertia in the subset data, whereas the second component accounted for 2.9% of inertia
(S1 Fig). For the first component, all of the negative outcomes of the dichotomous variables
were associated with negative scores, while all of the positive outcomes of the dichotomous
variables were associated with positive scores (S1 Fig). The variables with the greatest weight
in determining a positive score were a positive response towards HCV micro-elimination
among migrants, prisoners and sex workers and the integration of HCV testing and treatment
with migrant health services. Conversely, the responses that were associated with the most neg-
ative scores were not having HCV micro-elimination efforts among PWID, not having HCV
integration with harm reduction services, and a lack of HCV blood safety testing (S1 Fig).
The extracted row profiles for the countries from WHO recommendation MCA are pre-
sented in Fig 1. The countries with the highest scores were Cyprus, Netherlands, Portugal, Slo-
venia, and Sweden (all having similarity scores of 10). These countries responded positively to
all of the binary indicators in WHO recommendation similarity score. The lowest scoring
country was Bulgaria (score of 0), which responded negatively to all but two of the binary indi-
cators. All of the other scores ranged between 0 and 10, forming a distribution of countries
along the spectrum of policy elimination (Fig 1).
For the verified policies similarity score, we considered for inclusion all the questions under
the subheading “verified questions” in Table 2. We included the following variables: fibrosis HCV
treatment restrictions; NSP in the general population; OST in the general population; NSP in pri-
sons; OST in prisons; testing/screening for HCV in prisons; and the treatment of HCV in prisons.
The MCA of these variables yielded a two-dimensional solution in which the first component
accounted for 44.3% of the inertia in the data, and the second component accounted for 34.6% of
the inertia in the dataset (S2 Fig). The responses that mapped the closest to the first component
were whether a country had a verified policy in place or not, with positive values indicating the
presence of verified policies and negative values indicating the absence of verified policies. The
second dimension was interpreted as whether a policy was being implemented in practice. Nega-
tive values represent policies that are in place but not well implemented, and positive values repre-
sent policies that are in place and well implemented (S2 Fig). The coordinates for both of the
dimensions of the second policy similarity score were extracted and are presented in Fig 2.
Spain had the highest first component score (10) of the verified policies similarity score (i.e.
the presence or absence of verified policies), followed by Portugal (9.48), Sweden (9.48), Aus-
tria (9.48), and the United Kingdom (9.48). Bosnia and Herzegovina, which only had an OST
and NSP programme for non-incarcerated individuals, had the lowest score 3.87 (Fig 2).
Cyprus had the next lowest score, which also only had an OST and NSP programme, like
Ukraine, but were reported as being well implemented.
Spain had the highest score of the second component as well (the proportion of verified pol-
icies that are well implemented, according to the patient group respondent) with a maximum
score of 10 (Fig 2). The lowest score was Finland, which had a score of 5.54. The patient
respondent reported that of all the policies in place, NSP in the general population, OST in the
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Table 2. Likert point breakdown of questions and sub-questions considered for inclusion into the policy similarity scores.
Strong positive Weak positive Neutral Weak negative Strong negative Not applicable
Total responses, n 243 192 166 126 89 134
WHO recommendation questions, n (%)
GHSS monitoring goal 3 (1.2) 8 (4.2) 6 (3.6) 5 (4.0) 3 (3.4) 0 (0.0)
Policy barriers equity GHSS 5 (2.1) 8 (4.2) 8 (4.8) 3 (2.4) 1 (1.1) 0 (0.0)
Policy stigma and discrimination 0 (0.0) 8 (4.2) 9 (5.4) 5 (4.0) 3 (3.4) 0 (0.0)
WHO recommendation: Micro elimination sub-questions, n (%)
Generational cohort 2 (0.8) 3 (1.6) 11 (6.6) 4 (3.2) 5 (5.6) 0 (0.0)
Haemodialysis patients 16 (6.6) 3 (1.6) 4 (2.4) 2 (1.6) 0 (0.0) 0 (0.0)
Haemophilia patients 16 (6.6) 3 (1.6) 4 (2.4) 2 (1.6) 0 (0.0) 0 (0.0)
Men who have sex with men 5 (2.1) 9 (4.7) 6 (3.6) 3 (2.4) 2 (2.2) 0 (0.0)
Migrants� 2 (0.8) 3 (1.6) 6 (3.6) 7 (5.6) 7 (7.9) 0 (0.0)
Patients with advanced liver disease 12 (4.9) 9 (4.7) 2 (1.2) 2 (1.6) 0 (0.0) 0 (0.0)
People living with HIV 17 (7.0) 6 (3.1) 1 (0.6) 1 (0.8) 0 (0.0) 0 (0.0)
People who inject drugs� 9 (3.7) 9 (4.7) 4 (2.4) 3 (2.4) 0 (0.0) 0 (0.0)
Prisoners� 6 (2.5) 3 (1.6) 7 (4.2) 7 (5.6) 2 (2.2) 0 (0.0)
Sex workers� 2 (0.8) 5 (2.6) 4 (2.4) 8 (6.3) 6 (6.7) 0 (0.0)
Thalassaemia patients 9 (3.7) 1 (0.5) 5 (3.0) 3 (2.4) 7 (7.9) 0 (0.0)
Transgender people 1 (0.4) 1 (0.5) 7 (4.2) 9 (7.1) 7 (7.9) 0 (0.0)
Transplantation patients 17 (7.0) 5 (2.6) 1 (0.6) 0 (0.0) 2 (2.2) 0 (0.0)
Veteran/military personnel 6 (2.5) 3 (1.6) 5 (3.0) 3 (2.4) 8 (9.0) 0 (0.0)
WHO recommendation: Service integration sub-questions, n (%)
Alcohol use services 2 (0.8) 5 (2.6) 5 (3.0) 7 (5.6) 6 (6.7) 0 (0.0)
Blood safety� 17 (7.0) 4 (2.1) 1 (0.6) 3 (2.4) 0 (0.0) 0 (0.0)
Cancer prevention and management 3 (1.2) 8 (4.2) 7 (4.2) 5 (4.0) 2 (2.2) 0 (0.0)
Haemodialysis centres 16 (6.6) 4 (2.1) 3 (1.8) 2 (1.6) 0 (0.0) 0 (0.0)
Harm reduction services� 5 (2.1) 10 (5.2) 5 (3.0) 3 (2.4) 2 (2.2) 0 (0.0)
HIV treatment clinic 15 (6.2) 7 (3.6) 2 (1.2) 1 (0.8) 0 (0.0) 0 (0.0)
Migrant health services� 3 (1.2) 3 (1.6) 4 (2.4) 7 (5.6) 8 (9.0) 0 (0.0)
NCD prevention and management 2 (0.8) 4 (2.1) 7 (4.2) 6 (4.8) 6 (6.7) 0 (0.0)
STI and reproductive health clinics 5 (2.1) 11 (5.7) 5 (3.0) 2 (1.6) 2 (2.2) 0 (0.0)
Verified questions, n (%)
Drug and alcohol restriction�� 5 (2.1) 6 (3.1) 4 (2.4) 2 (1.6) 1 (1.1) 7 (5.2)
Non-hospital testing 3 (1.2) 3 (1.6) 3 (1.8) 2 (1.6) 1 (1.1) 13 (9.7)
Non-hospital treatment 0 (0.0) 5 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 20 (14.9)
Non-specialist treatment 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0) 24 (17.9)
NSP general population�� 5 (2.1) 5 (2.6) 6 (3.6) 4 (3.2) 1 (1.1) 4 (3.0)
NSP prison�� 0 (0.0) 0 (0.0) 2 (1.2) 1 (0.8) 0 (0.0) 22 (16.4)
OST general population�� 8 (3.3) 6 (3.1) 5 (3.0) 2 (1.6) 0 (0.0) 4 (3.0)
OST prison�� 4 (1.6) 5 (2.6) 4 (2.4) 2 (1.6) 1 (1.1) 9 (6.7)
Testing and screening of HCV in prisons�� 2 (0.8) 5 (2.6) 4 (2.4) 3 (2.4) 2 (2.2) 9 (6.7)
Treatment of HCV in prisons�� 3 (1.2) 6 (3.1) 3 (1.8) 3 (2.4) 1 (1.1) 9 (6.7)
Fibrosis treatment restrictions for HCV�� 7 (2.9) 3 (1.6) 1 (0.6) 1 (0.8) 0 (0.0) 13 (9.7)
Variables denoted with � were included into the first similarity score based off WHO recommendations and variables that are marked with �� were included into the
second similarity score based off verified policies. GHSS = Global Health Sector Strategy, NCD = non-communicable disease, STI = sexually transmitted infection,
NSP = needle-syringe programme, OST = opioid substitution therapy, HCV = hepatitis C virus
https://doi.org/10.1371/journal.pone.0235715.t002
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general population, and HCV testing/screening in prisons were being adequately imple-
mented. However, drug–alcohol restrictions, the lifting of fibrosis severity HCV treatment
restrictions, and HCV treatment in prisons were not well implemented.
Table 3 presents the reported similarity score for WHO recommendations, the two similar-
ity scores for the verified policies, the difference between the WHO recommendation similar-
ity score and the first verified policy similarity score for each applicable country, and the mean
confidence score of the respondent for each country. Positive values of the difference between
WHO recommendation similarity score and the first similarity score for the verified policies
may reflect poor engagement with patients in the discussion of the current status of HCV elim-
ination in their country. Negative values of this difference could suggest poor implementation
of policies. The country with the largest negative gap between the verified policy similarity
Fig 1. WHO recommendation similarity scores for the studied countries. Summary of the standardized scores for the different countries according to row profiles of
the first components of the MCA.
https://doi.org/10.1371/journal.pone.0235715.g001
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score and WHO recommendation score was Bulgaria, with a difference of –7.86. The largest
positive gap was Cyprus, with a difference of 5.59 between WHO recommendation score and
the first dimension of the verified policy similarity score. The mean confidence score for Bul-
garia was 2.53, and for Cyprus the mean confidence score was 3.38 (Table 3).
Discussion
The Hep-CORE 2018 study focused on how well countries were implementing WHO recom-
mendations from the GHSS as well as verified policies to eliminate viral hepatitis. We analyzed
Fig 2. Verified policy similarity scores for the different countries (n = 20). The similarity score of the countries based on their responses to the verified questions and
whether a particular policy was in place.
https://doi.org/10.1371/journal.pone.0235715.g002
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the similarity of different country responses for a subset of WHO recommendations and a sub-
set of verified policy questions. Patient group respondents in 25 countries indicated incom-
plete implementation of WHO recommended HCV policy implementation across Europe,
with concerning intercountry discrepancies evidenced.
Currently, only 12 countries are reported to be on track to meet WHO elimination targets
for HCV—eight of these are in WHO European Region and seven were among our study
countries [19]. Countries that are on track and included in this study are Egypt, the Nether-
lands, Spain, Switzerland, and the UK. France and Italy are both on track and patients’ groups
were sent surveys but did not respond. For Egypt and Switzerland, we did not calculate a dif-
ference because both countries were excluded from the verified similarity analysis and there-
fore did not have a score. The difference for both the UK and Spain were negative, suggesting
the under-implementation of policies from the perspective of the respondents. In contrast, the
Netherlands had a positive difference, suggesting that policy-makers and the medical commu-
nity could better engage patient advocacy groups to highlight policies that are in place.
Although Egypt and Switzerland did not have a score generated from the verified similarity
score, both had low scores (6.29 and 4.71, respectively) relative to the possible maximum of 10
Table 3. The WHO recommendation similarity score of the two similarity scores from the verified policies, the difference between WHO recommendation score





Difference of WHO score and





Bulgaria 0 7.86 -7.86 7.5 2.53 (0.77)
Spain 6.29 10 -3.71 10 2.65 (0.61)
Poland 4.32 7.59 -3.27 5.55 3.24 (0.75)
Finland 5.89 8.71 -2.82 5.54 3.11 (0.46)
Romania 5.4 7.21 -1.81 8.39 3.29 (0.69)
United Kingdom 7.77 9.48 -1.71 9.71 3.70 (0.66)
Austria 7.77 9.48 -1.71 9.71 3.06 (0.64)
Croatia 6.29 7.25 -0.96 8.71 3.56 (0.51)
Norway 5.33 6.25 -0.92 8.91 3.21 (0.89)
Denmark 8.79 8.91 -0.12 5.76 1.95 (0.52)
Belgium 8.98 8.63 0.35 9.7 2.12 (0.81)
Sweden 10 9.48 0.52 9.71 3.11 (0.83)
Portugal 10 9.48 0.52 8.74 3.89 (0.32)
Ukraine 6.57 5.83 0.74 6.74 2.71 (0.47)
Bosnia and
Herzegovina
4.71 3.87 0.84 7.99 2.69 (0.48)
Serbia 6.2 4.84 1.36 8.29 3.56 (0.63)
Slovenia 10 8.63 1.37 9.7 3.76 (0.44)
Netherlands 10 8.62 1.38 9.32 2.67 (0.97)
Slovakia 8.51 6.78 1.73 9.06 3.19 (0.40)
Cyprus 10 4.41 5.59 8.65 3.38 (0.51)
Switzerland 4.71 NA NA NA 3.77 (0.44)
Egypt 6.29 NA NA NA 3.90 (0.32)
Turkey 2.22 NA NA NA 3.83 (0.39)
North Macedonia 4.71 NA NA NA 3.42 (0.52)
Israel 4.71 NA NA NA 4.00 (0)
ProcrastiNation NA 9.22 NA 0 NA
ElimiNation 10 10 - 10 NA
StagNation 0 0 - 8.52 NA
https://doi.org/10.1371/journal.pone.0235715.t003
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for WHO recommendation similarity score. These low scores indicate that vulnerable groups,
such as migrants, are not targeted well. This finding highlights an issue with WHO 2030 goals
and what is considered the “elimination” of HCV as a public health threat. For example, there
is a good probability that both Switzerland and Egypt will meet the WHO 2030 HCV elimina-
tion targets at a population level despite not targeting all vulnerable groups. As a consequence,
some vulnerable groups may be left behind. Therefore, it is important to assess if and how the
most vulnerable and/or marginalized patients are included in policy and implementation of
governmental HCV elimination strategies, even if a country might be on track for HCV elimi-
nation. This idea is further reinforced by the findings of the recent Lancet Commission on the
acceleration of viral hepatitis elimination [14]. In the Commission, a policy score card was cre-
ated for select countries, including five (Egypt, Poland, Romania, Spain, and the UK) that over-
lap with our study. The scores we generated indicated that Egypt could be leaving
marginalized populations, like PWID, behind. Likewise, the Lancet Commission, found that
Egypt does not have a harm reduction policy in place. The Lancet Commission also identified
policy gaps in Poland and Romania, such as the lack of a publicly-funded screening pro-
gramme and reliable national epidemiological data, which supports the low scores we recorded
for the countries in this study. Conversely, the Commission reported that Spain and the UK
have both of these policies in place, and we found that these countries scored highly, outrank-
ing Egypt, Poland, and Romania [14].
Limitations
The Hep-CORE 2018 study relies on only one stakeholder group for information; therefore,
inferential statistics cannot be conducted at the country level as we only have a single replicate.
Additionally, this means that a random sample was not possible as we could not randomly
select from any groups. Although, a random sample for this kind of research is not desirable
since we surveyed key stakeholders whose perspectives were most relevant to the research
questions rather than those of random patient groups. We understand that our sampling
method could introduce a bias since respondents likely had similar education and sociodemo-
graphic characteristics. However, this selection is desirable in our study as we tried to obtain
an accurate view of HCV policy implementation from patient groups rather than determine
patients’ knowledge about HCV policy. Furthermore, the survey could not be altered once it
was launched, potentially leading to outcome censoring if a policy changed while the survey
was being completed. For example, this survey was conducted in Q4 2018, but Egypt started a
national screening programme that would include all subgroups in the study in Q2 2019,
which would not be captured by this study. Furthermore, Egypt’s new approach is representa-
tive of where a macro-elimination approach is possible due to government commitment, and
micro-elimination in this scenario is not necessarily needed [26]. Another limitation of the
cross-sectional nature of this study is that a policy might not have been in place long enough
for a patient group to accurately evaluate its implementation. In the future, it would be ideal if
the data needed to build the score could be collected every 6 months and serve as a progress
monitoring tool; however, a lack of funding constrains the ability to create such projects and
efforts. Additionally, involving drug user groups and other organisations whose members
might not be well represented by patient groups would strengthen reporting. Additionally, the
survey was only disseminated in English, which may have limited the accuracy of the responses
as most respondents were non-native English speakers.
For future studies, it will be important to explore new approaches to hepatitis policy moni-
toring, such as cross-referencing data collected from civil society with the data from other
sources including publicly available DAA reimbursement records, government health officials,
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and clinicians. The generalizability of the MCA method used to evaluate the responding coun-
tries is another important limitation. MCA methods used to make the similarity scores tend to
produce unstable results because they depend on the sample used. The inclusion of anomalous
data, choices carried out by the researchers when reducing the categories of the variables, and
other factors could have affected the final results and country rankings [27]. However, the use
of standardized countries helped stabilize those estimates and provide meaning to the numeri-
cal values of the similarity score, a technique we have validated elsewhere [28]. Although, that
study does not levy patient or civil society information like this present study. Finally, noting
that the scores are derived from patient responses, these policy similarity scores should not be
used in isolation but as an aid in decisionmaking [29].
Conclusions
Patient groups from all 25 studied countries identified areas of improvement in HCV policy
development and implementation with substantial inter-country variation. Policy improve-
ments are essential for the entire European Region to achieve the WHO 2030 viral hepatitis
elimination goal. Civil society and the government must take more action to monitor imple-
mentation of current policies. Crucially, European countries must ensure acceptable and
accessible HCV service provision for high-risk populations, who continue to be overlooked in
many settings.
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